Preferred Label : Anti-CD79b Antibody-drug Conjugate SHR-A1912;
NCIt synonyms : ADC SHR-A1912; Anti-CD79b ADC SHR-A1912;
NCIt definition : An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated
antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b;
B-cell-specific glycoprotein B29) conjugated to a topoisomerase-1 inhibitor, with
potential antineoplastic activity. Upon intravenous administration, the monoclonal
antibody moiety of anti-CD79b ADC SHR-A1912 targets and binds to CD79b expressed on
tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released
and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and
resulting in cell cycle arrest and apoptosis in tumor cells expressing CD79b. CD79b,
a critical receptor for successful B-cell development and part of the B-cell receptor
(BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas.;
Molecule name : SHR A1912; SHR-A1912;
NCI Metathesaurus CUI : CL1773824;
Origin ID : C185413;
UMLS CUI : C5666987;
Semantic type(s)
- concept_is_in_subset
- has_target
